The results suggested that PRL-increasing and PRL-sparing antipsychotics pose a similar risk of breast cancer (OR, 1.13; 95% CI, approximately 0.97–1.31), with very low heterogeneity, as shown in Figure 4. Here, PRL is linked to breast carcinoma.